AXGN · AxoGen, Inc.
$39.49
+0.02% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
56.5
Dividend yield
—
Beta
1.09
Avg volume
1M
Employees
1K
2D change
—
5D change
3.55%
10D change
3.24%
30D change
-8.44%
60D change
4.20%
MTD change
-6.54%
YTD change
25.70%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AXGN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-04-29
Latest call per bank · past 12 months
Wells Fargo
Overweight$48.00
+21.5% vs priceJefferies
Buy$36.00
-8.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-04-29 | Canaccord Genuity | Maintains | Buy | $45.00 → $50.00 |
| 2026-04-29 | Citizens | Maintains | Market Outperform | $42.00 → $50.00 |
| 2026-04-29 | Wells Fargo | Maintains | Overweight | $40.00 → $48.00 |
| 2026-04-29 | HC Wainwright & Co. | Maintains | Buy | $39.00 → $50.00 |
| 2026-04-23 | Lake Street | Maintains | Buy | $40.00 → $50.00 |
| 2026-03-30 | Canaccord Genuity | Maintains | Buy | $40.00 |
| 2026-02-24 | Citizens | Maintains | Market Outperform | $34.00 → $42.00 |
| 2026-02-19 | Wells Fargo | Initiates | Overweight | $0.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 49 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.1% below the 50-day MA ($42.04).
- Price vs 200-day MA: Trading 22.6% above the 200-day MA ($33.57).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.06) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.55) and high ($46.19).
AXGN Price Chart
Loading chart for AXGN…
Fundamentals
About AxoGen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
More in Medical Devices
ABT
Abbott Laboratories
$182B -15.0% YTD
SYK
Stryker Corporation
$129B -3.7% YTD
MDT
Medtronic plc.
$108B -10.8% YTD
BSX
Boston Scientific Corporation
$68B -52.3% YTD
EW
Edwards Lifesciences Corporatio
$48B -2.6% YTD
GEHC
GE HealthCare Technologies Inc.
$28B -25.4% YTD
DXCM
DexCom, Inc.
$28B 10.5% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.